A Phase 1 interventional study of HRS-8080 Tablet and Itraconazole Capsule in Breast Cancer, sponsored by Shandong Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-14.
Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing HRS-8080 in Breast Neoplasms — 8 open to participants now, 8 under way, 3 of them phase 3. HRS-8080 · Breast Neoplasms.
Among the 11 studies testing HRS-8080 in Breast Neoplasms, this one is the 10th largest by enrollment, is one of 3 that started in 2025, is one of 4 in phase 1, and was the 6th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →8 of the 11 studies testing HRS-8080 in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18–75 · Women only
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18–75 · Women only
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18–75 · Women only
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18–75 · Women only
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18–75 · Women only
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 4 · Phase 3 3
First in 2023; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 180 across the 11 interventional studies. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
This study is registered under Shandong Suncadia Medicine Co., Ltd., one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Shandong Suncadia Medicine Co., Ltd. is the lead sponsor of 87 studies on the registry; 39 are open to participants now.
53 studies in Breast Neoplasms by Jiangsu HengRui Medicine Co., Ltd.: 18 open now, 27 under way, 12 of them phase 3. Of 17 finished, 0 (0%) have results posted.
Among the 53 studies in Breast Neoplasms by Jiangsu HengRui Medicine Co., Ltd., this one is the 49th largest by enrollment, is one of 6 that started in 2025, is one of 19 in phase 1, and was the 44th registered.
Jiangsu HengRui Medicine Co., Ltd.’s Breast Neoplasms studies by the year they started, since 2011.
2 of the studies testing HRS-8080 in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07024173Phase 3Shandong Suncadia Medicine Co., Ltd.A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer | 2027-08 |
| NCT07876596Shandong Suncadia Medicine Co., Ltd.A Drug-Drug Interaction Study of Rifampicin and Oral HRS-8080 | 2027-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies testing HRS-8080 in Breast Neoplasms, from their registry updates:
Among Jiangsu HengRui Medicine Co., Ltd.’s 53 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a phase I study to evaluate the effect of Itraconazole on the pharmacokinetics of HRS-8080 in healthy participants and the safety of HRS-8080 administered alone and in combination with Itraconazole in healthy participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: HRS-8080 Tablet · Drug: Itraconazole Capsule
HRS-8080 tablet, specified dose on specified days.
Itraconazole capsule, specified dose on specified days.
Maximum concentration (Cmax) of HRS-8080.
Time frame: From Day 1 to Day 11.
Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUClast) of HRS-8080.
Time frame: From Day 1 to Day 11.
Area under the plasma concentration-time curve from time zero to infinity (AUCinf) of HRS-8080.
Time frame: From Day 1 to Day 11.
Time to maximum plasma concentration (Tmax) of HRS-8080.
Time frame: From Day 1 to Day 11.
Terminal elimination half-life (t1/2) of HRS-8080.
Time frame: From Day 1 to Day 11.
Apparent volume of distribution (Vz/F) of HRS-8080.
Time frame: From Day 1 to Day 11.
Clearance (CL/F) of HRS-8080.
Time frame: From Day 1 to Day 11.
Adverse events (AEs).
Time frame: From Day 1 to Day 17.
Serious adverse events (SAEs).
Time frame: From Day 1 to Day 17.
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Nov 2025 to primary completion in Dec 2025, 1 month.
Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 1 month is below that.
Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HRS-8080
Shandong Suncadia Medicine Co., Ltd. →